Regeneron Confirms that REGN-COV2 Antibody Cocktail Provided to President Trump Under Compassionate Use Request

October 2, 2020 --  Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today confirmed that, as announced by the White House Press Secretary, Regeneron provided a single 8 gram dose of REGN-COV2, a cocktail of two monoclonal antibodies, for use by...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials